StockData

Liquidia vs MannKind

LQDA and MNKD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LQDA and MNKD compare

Liquidia is the larger company, worth 3.9 times as much as MannKind ($5.1B against $1.3B).

Liquidia grew revenue faster over the last twelve months (2234% versus 30.5% for MannKind).

Liquidia keeps more of each dollar of sales as profit, with a net margin of 30.7% compared with −11.1% at MannKind.

Liquidia scores higher on the StockData Score (8 against 6 for MannKind), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLQDAMNKD
Size and price
Market cap$5.1B$1.3B
Share price$56.73$4.07
Change, 1 year102%−19.6%
Change, 5 years1280%−12.1%
Beta (5Y)1.001.98
Employees216241
StockData Score
Total score8 (better)6
Valuation score01 (better)
Growth score22
Performance score3 (better)2
Health score3 (better)1
Dividend score00
Valuation
P/E40.8×–
P/S11.3×3.3× (better)
P/B26.0×–
EV/EBITDA28.2× (better)39.8×
P/FCF33.7×–
FCF yield3.0% (better)−1.4%
Fair value$32.46$1.79
Margin of safety−74.8% (better)−127%
Growth
Revenue growth (TTM)2234% (better)30.5%
Revenue growth, 5Y average192% (better)39.9%
Net income growth (TTM)–−233%
EPS growth (TTM)–−218%
Profitability
Gross margin–89.8%
Operating margin37.4% (better)2.3%
Net margin30.7% (better)−11.1%
FCF margin33.4% (better)−4.6%
Return on equity132%–
Financial health
Interest coverage6.3× (better)0.3×
Current ratio2.31 (better)1.72
Altman Z-score10.49 (better)−4.45
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions81.1%56.7%
Held by insiders19.5%2.5%
Insider net buying, 12 months−$227M−$2.9M (better)
Short interest, % of float24.3%8.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.